Expression of P16 and CD44 in gastrointestinal stromal tumors and their relationship with the prognosis ;of patients
10.3969/j.issn.1006-5725.2016.14.024
- VernacularTitle:P16和CD44在胃肠间质瘤中的表达及其与预后的关系
- Author:
Enyi SHI
;
Xiaoru WANG
;
Xiaoning LI
;
Xu CAI
;
Xiongzeng ZHU
- Publication Type:Journal Article
- Keywords:
Gastrointestinal stromal tumors;
P16;
CD44;
Prognosis;
Tissue microarray
- From:
The Journal of Practical Medicine
2016;32(14):2333-2337
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the expression of P16 and CD44 in gastrointestinal stromal tumors (GIST) and their relationship with the prognosis of patients. Methods The GIST specimens of seventy patients who received surgical excision were collected. Tissue microarray of the seventy GIST samples was constructed. The expression of P16 and CD44 were detected by the immunohistochemical staining. The patients were followed up via out-patient examination and telephone. Results All the patients were followed up for 2-212 months, and the median time for follow-up was 68 months. The differences of the expression of P16 in GISTs among NIH risk ranks were insignificant (P > 0.05). The differences of the expression of CD44 in GISTs among NIH risk ranks were statistically significant (P < 0.05). Univariate analysis showed that tumor size, mitotic count, tumor location, NIH risk rank, the expression of P16 and CD44 were related to the prognosis of GIST patients. Multivariate showed that tumor size, mitotic count, tumor location, and the expression of CD44 was independent prognosis factors of GIST patients. Conclusion CD44 could be used as a biomarker in predicting the prognosis of GIST patients.
